jeffbetcasino| U.S. stocks move | Novo Nordisk fell more than 2%, Amgen's mid-term trial of a new weight-loss drug gains positive data_Sports

Index/
Sports/jeffbetcasino| U.S. stocks move | Novo Nordisk fell more than 2%, Amgen's mid-term trial of a new weight-loss drug gains positive data

jeffbetcasino| U.S. stocks move | Novo Nordisk fell more than 2%, Amgen's mid-term trial of a new weight-loss drug gains positive data

2024-05-04 editor Views(7)

诺和诺德(LLYjeffbetcasino.US)跌超2%至121.29美元。消息面上，安进减肥新药中期试验获积极数据，如果该药物获得批准，它将与诺和诺德jeffbetcasino的Wegovy和礼来的Zepbound竞争。

jeffbetcasino| U.S. stocks move | Novo Nordisk fell more than 2%, Amgen's mid-term trial of a new weight-loss drug gains positive data

此前有媒体称，安进正在尝试一种全新的减肥药，作用机理与诺和诺德和礼来的产品存在差异，可以令患者即使停药，体重也不会反弹。

This article is reproduced from the Internet. If there is infringement, please contact to delete